Two chemotherapy drugs plus radiation before pancreatic surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether giving two already-approved chemotherapy drugs and radiation before surgery works better for localized pancreatic cancer. It’s meant for people whose cancer looks removable by surgery and who haven’t had prior pancreatic cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed pancreatic cancer (adenocarcinoma), proven by biopsy or body fluid testing
- Your cancer is localized and potentially removable by surgery (not metastatic or borderline resectable)
- You are 18 years or older
- You can carry out most daily activities (performance status 0–1)
- Your blood counts and liver/kidney labs meet the study thresholds (enough white cells, platelets, and normal-ish liver/kidney function)
- You have not had any prior treatment for pancreatic cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
This trial compares two approaches for patients with pancreatic or periampullary cancer that can be surgically removed: getting chemotherapy before surgery (neoadjuvant therapy) versus surgery first. It aims to find out which sequence leads to better outcomes.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests a combination of three chemotherapy drugs given before surgery for pancreatic cancer that is removable or borderline removable. The goal is to shrink the tumor to make surgery more successful.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Pancreas Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.